Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200
Debt
Debt-to-Equity Ratio0.13
Current Ratio2.41
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-0.27
Forward P/E Ratio-0.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.07 million
Price / Sales2.79
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book10.23
Profitability
EPS (Most Recent Fiscal Year)($23.72)
Net Income$-21,610,000.00
Net Margins-561.47%
Return on Equity-445.14%
Return on Assets-196.63%
Miscellaneous
Employees95
Outstanding Shares2,270,000
Market Cap$16.33
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) posted its earnings results on Tuesday, May, 15th. The medical research company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. The medical research company earned $0.81 million during the quarter, compared to the consensus estimate of $1.21 million. Biocept had a negative return on equity of 445.14% and a negative net margin of 561.47%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 equities research analysts have issued 12-month price targets for Biocept's stock. Their forecasts range from $1.00 to $1.50. On average, they anticipate Biocept's stock price to reach $1.25 in the next year. This suggests that the stock has a possible downside of 80.0%. View Analyst Ratings for Biocept.
What is the consensus analysts' recommendation for Biocept?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Biocept's key competitors?
Some companies that are related to Biocept include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Foundation Medicine (FMI), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Enzo Biochem (ENZ), Celcuity (CELC), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Psychemedics (PMD).
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 55)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations, Sec. & Principal Accounting Officer (Age 60)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg M.S.E, Associate Director of Technology Devel.
Has Biocept been receiving favorable news coverage?
Headlines about BIOC stock have been trending positive on Wednesday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biocept earned a media sentiment score of 0.35 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 46.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $6.24.
How big of a company is Biocept?
Biocept has a market capitalization of $16.33 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($23.72) on an earnings per share basis. Biocept employs 95 workers across the globe.
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
